These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 11147229

  • 21. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Sancho JM, Ribera JM, Xicoy B, Morgades M, Oriol A, Tormo M, del Potro E, Debén G, Abella E, Bethencourt C, Ortín X, Brunet S, Ortega-Rivas F, Novo A, López R, Hernández-Rivas JM, Sanz MA, Feliu E, PETHEMA Group.
    Eur J Haematol; 2007 Feb; 78(2):102-10. PubMed ID: 17087744
    [Abstract] [Full Text] [Related]

  • 22. Comparison between Hyper-CVAD and PETHEMA ALL-93 in Adult Acute Lymphoblastic Leukemia: A Single-Center Study.
    Erkut N, Akidan O, Selim Batur D, Karabacak V, Sonmez M.
    Chemotherapy; 2018 Feb; 63(4):207-213. PubMed ID: 30304722
    [Abstract] [Full Text] [Related]

  • 23. Hyper-CVAD regimen in routine management of adult acute lymphoblastic leukemia: a retrospective multicenter study.
    Buyukasik Y, Acar K, Kelkitli E, Uz B, Serefhanoglu S, Ozdemir E, Pamukcuoglu M, Atay H, Bektas O, Sucak GT, Turgut M, Aksu S, Yagci M, Sayınalp N, Ozcebe OI, Goker H, Haznedaroglu IC.
    Acta Haematol; 2013 Feb; 130(3):199-205. PubMed ID: 23797290
    [Abstract] [Full Text] [Related]

  • 24. High-dose sequential (HDS) chemotherapy for high-risk non-Hodgkin's lymphoma: long-term analysis and future developments.
    Tarella C, Cuttica A, Caracciolo D, Zallio F, Ricca I, Bergui L, Gavarotti P, Marinone C, Pagano M, Rossi G, de Crescenzo A, Salomone A, Ladetto M, Boccadoro M, Pileri A.
    Ann Hematol; 2001 Feb; 80 Suppl 3():B123-6. PubMed ID: 11757693
    [No Abstract] [Full Text] [Related]

  • 25. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
    Mahoney DH, Camitta BM, Leventhal BG, Shuster JJ, Civin CJ, Ganick DJ, Lauer SJ, Steuber CP, Kamen BA.
    Cancer; 1995 May 15; 75(10):2623-31. PubMed ID: 7736409
    [Abstract] [Full Text] [Related]

  • 26. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).
    Rytting ME, Thomas DA, O'Brien SM, Ravandi-Kashani F, Jabbour EJ, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Cortes JE, Borthakur G, Garris R, Cardenas-Turanzas M, Schroeder K, Jorgensen JL, Kornblau SM, Kantarjian HM.
    Cancer; 2014 Dec 01; 120(23):3660-8. PubMed ID: 25042398
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
    Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF.
    J Clin Oncol; 2005 Oct 01; 23(28):7013-23. PubMed ID: 16145068
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy.
    Garg R, Kantarjian H, Thomas D, Faderl S, Ravandi F, Lovshe D, Pierce S, O'Brien S.
    Cancer; 2009 May 15; 115(10):2147-54. PubMed ID: 19298009
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Progressive paresthesia and weakness after intrathecal chemotherapy.
    Marshall R, Gupta ND, Palacios E, Neitzschman HR.
    J La State Med Soc; 2008 May 15; 160(2):92-4. PubMed ID: 18681351
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Feasibility and outcome of the hyper-CVAD regimen in patients with adult acute lymphoblastic leukemia.
    Portugal RD, Loureiro MM, Garnica M, Pulcheri W, Nucci M.
    Clin Lymphoma Myeloma Leuk; 2015 Jan 15; 15(1):52-7. PubMed ID: 25037887
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.
    Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, Pemmaraju N, Daver N, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Yin CC, Khoury JD, Jorgensen J, Estrov Z, Bohannan Z, Konopleva M, Kadia T, Jain N, DiNardo C, Wierda W, Jeanis V, O'Brien S.
    Lancet Oncol; 2015 Nov 15; 16(15):1547-1555. PubMed ID: 26432046
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.